Discussion of Hepatitis B Vaccine: Prospects for Duration of Immunity by McCollum, Robert W.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 60 (1987), 339
Discussion ofHepatitis B Vaccine: Prospects for
Duration ofImmunity
ROBERT W. McCOLLUM, M.D.
Dean, Dartmouth MedicalSchool, Hanover, NewHampshire
Received February 10, 1987
When Al Evans started exploring thehepatitis field almost forty years ago, hehad to
do so with the techniques ofthe time. In retrospect, these were usually inadequate for
answering the questions being asked. He did try new approaches, derived from recent
clinical observations, and new developments in biochemical and liver biopsy methods.
His work added significantly to the evaluation of steroid therapy in acute viral
hepatitis, and his attempts at experimental transmission, particularly in primates, took
advantage ofhis epidemiologic and clinical studies. Although he subsequently left the
full "active duty" ranks of persistent hepatitis explorers, he has remained a close
observer and helpful consultant. My guess is that today he can still muster some
nostalgic thoughts about a serum known to be infective (HBV) and some immune or
clinically "unresponsive" chimpanzees, as well as some then-unprovable hypotheses
about hepatitis recurrence, reinfection, immunity, and multiple etiologies, even
including mononucleosis. At that time, few could envision any reasonable expectation
for the relatively clear answers we have today, and probably fewer still expected the
development ofan effective vaccine against even one ofthe elusive hepatitis viruses.
Saul Krugman was a most appropriate person to initiate the human testing of the
first pilot production lot of hepatitis B vaccine, since it was a derivative of his earlier
hepatitis transmission studies and the demonstrated specific protective effect of
antibodies (HBsAb). The individuals (including Saul himself) whovolunteered for the
first human trial were relatively easily followed for development of HBsAb. Since the
study involved "at-risk" but not "high-risk" subjects and did not include a "control"
group, protective efficacy could not be established as it clearly was in the subsequent
field trials among "high-risk" groups. Early results of long-term antibody duration
studies among Krugman's original group appeared to be disappointing, with a 15
percent reversion to"negative" status infivetoseven years. Hehasnow "challenged" a
large segment of the original group, using the newly produced DNA recombinant
vaccine. In addition to further demonstrating its safety, the results he has presented
today indicate clearly that the timing ofthe "booster" response is well within the usual
incubation period for HBV and, by analogy, that, in the long run, protective efficacy
may extend well beyond theduration ofmeasurable levels ofserum antibodies. Had he
waited longer than five to seven years to measure residual antibody levels, it is likely
that the proportion of "negatives" would have been greater than 15 percent and that,
among those, after challenge with the new vaccine, the proportion of low-level boosts
and of "non-responders" would also have been greater. Until such measurements can
beobtained from the field and their meaning in relation tochallenge byinfectious virus
can be ascertained, however, we can take comfort in the results presented today.
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